Longbow Research cut shares of Cambrex (NYSE:CBM) from a buy rating to a neutral rating in a report issued on Wednesday morning, Marketbeat reports.
A number of other research analysts also recently issued reports on the company. William Blair began coverage on Cambrex in a report on Tuesday, January 16th. They set an outperform rating on the stock. Zacks Investment Research raised Cambrex from a strong sell rating to a hold rating in a report on Monday, January 15th. Finally, Craig Hallum reaffirmed a buy rating and set a $60.00 price target (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Cambrex presently has an average rating of Hold and an average target price of $60.00.
Cambrex (NYSE:CBM) opened at $52.80 on Wednesday. The stock has a market capitalization of $1,737.60, a price-to-earnings ratio of 17.20, a PEG ratio of 1.28 and a beta of 2.38. Cambrex has a 1-year low of $42.55 and a 1-year high of $62.95.
Cambrex (NYSE:CBM) last announced its quarterly earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.17. The firm had revenue of $182.28 million for the quarter, compared to the consensus estimate of $181.39 million. Cambrex had a return on equity of 22.42% and a net margin of 19.17%. The company’s quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.23 earnings per share. equities analysts predict that Cambrex will post 2.76 EPS for the current fiscal year.
Several large investors have recently made changes to their positions in CBM. Brown Advisory Inc. lifted its holdings in shares of Cambrex by 454.1% during the fourth quarter. Brown Advisory Inc. now owns 895,240 shares of the biotechnology company’s stock valued at $42,972,000 after purchasing an additional 733,663 shares in the last quarter. William Blair Investment Management LLC increased its position in Cambrex by 35.8% during the fourth quarter. William Blair Investment Management LLC now owns 2,353,032 shares of the biotechnology company’s stock valued at $112,946,000 after acquiring an additional 620,098 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in Cambrex during the fourth quarter valued at $22,203,000. Boston Partners increased its position in Cambrex by 118.5% during the fourth quarter. Boston Partners now owns 709,786 shares of the biotechnology company’s stock valued at $34,069,000 after acquiring an additional 384,897 shares during the last quarter. Finally, Peregrine Capital Management LLC purchased a new stake in Cambrex during the fourth quarter valued at $9,780,000.
ILLEGAL ACTIVITY WARNING: “Cambrex (CBM) Downgraded to Neutral at Longbow Research” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/18/cambrex-cbm-downgraded-to-neutral-at-longbow-research.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.